Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Daiichi Sankyo
McKesson
Covington
Harvard Business School
Argus Health
US Department of Justice
Baxter
Johnson and Johnson

Generated: July 19, 2018

DrugPatentWatch Database Preview

Bayer Hlthcare Company Profile

« Back to Dashboard

Summary for Bayer Hlthcare
International Patents:1385
US Patents:46
Tradenames:57
Ingredients:38
NDAs:58

Drugs and US Patents for Bayer Hlthcare

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare GADAVIST gadobutrol SOLUTION;INTRAVENOUS 201277-002 Mar 14, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up
Bayer Hlthcare CIPRO XR ciprofloxacin; ciprofloxacin hydrochloride TABLET, EXTENDED RELEASE;ORAL 021473-002 Aug 28, 2003 DISCN No No 7,709,022*PED ➤ Sign Up Y ➤ Sign Up
Bayer Hlthcare LEVITRA vardenafil hydrochloride TABLET;ORAL 021400-001 Aug 19, 2003 RX Yes No 7,696,206 ➤ Sign Up Y Y ➤ Sign Up
Bayer Hlthcare BILTRICIDE praziquantel TABLET;ORAL 018714-001 Dec 29, 1982 AB RX Yes Yes ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Bayer Hlthcare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Hlthcare GADAVIST gadobutrol SOLUTION;INTRAVENOUS 201277-004 Mar 14, 2011 5,980,864 ➤ Sign Up
Bayer Hlthcare MENOSTAR estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 021674-001 Jun 8, 2004 5,891,868 ➤ Sign Up
Bayer Hlthcare MAGNEVIST gadopentetate dimeglumine INJECTABLE;INJECTION 021037-001 Mar 10, 2000 5,362,475 ➤ Sign Up
Bayer Hlthcare FINACEA azelaic acid GEL;TOPICAL 021470-001 Dec 24, 2002 4,713,394 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for BAYER HLTHCARE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 3 mg/0.02 mg/0.451 mg and 0.451 mg ➤ Subscribe 2012-11-13
➤ Subscribe Tablets 25 mg, 50 mg and 100 mg ➤ Subscribe 2005-03-22
➤ Subscribe Tablets 200 mg ➤ Subscribe 2014-02-28
➤ Subscribe Tablets 3 mg/0.02 mg ➤ Subscribe 2006-09-29
➤ Subscribe Tablets 40 mg ➤ Subscribe 2016-09-27
➤ Subscribe Transdermal System 0.05 mg/day and 0.1 mg/day ➤ Subscribe 2005-09-12
➤ Subscribe Tablets 0.5 mg, 1 mg,1.5 mg, 2 mg and2.5 mg ➤ Subscribe 2017-10-10
➤ Subscribe Tablets 5 mg ad 10 mg ➤ Subscribe 2009-07-10
➤ Subscribe Oral Suspension 250 mg/5 mL and 500 mg/ 5 mL ➤ Subscribe 2009-10-16
➤ Subscribe Gel 0.05% ➤ Subscribe 2010-12-01
➤ Subscribe Orally Disintegrating Tablets 10 mg ➤ Subscribe 2011-12-22
➤ Subscribe Tablets 3 mg/0.03 mg/0.451 mg and 0.451 mg ➤ Subscribe 2012-09-28
➤ Subscribe Injection 1.6 mg/mL ➤ Subscribe 2014-02-07
➤ Subscribe Tablets 0.5 mg/1 mg ➤ Subscribe 2007-12-26
➤ Subscribe Tablets 0.25 mg/0.5 mg ➤ Subscribe 2015-01-08
➤ Subscribe Tablets 3 mg/0.03 mg ➤ Subscribe 2005-01-07
➤ Subscribe Topical Foam 15% ➤ Subscribe 2017-09-14
➤ Subscribe Tablets 20 mg ➤ Subscribe 2009-03-05
➤ Subscribe Tablets 2.5 mg ➤ Subscribe 2009-09-04
➤ Subscribe Tablets 3 mg; 2 mg/2 mg; 2 mg/3 mg; 1 mg ➤ Subscribe 2010-10-22
➤ Subscribe Tablets 3 mg/0.02 mg/0.451 mg and 0.451 mg ➤ Subscribe 2011-11-21
➤ Subscribe Gel 15% ➤ Subscribe 2012-07-27
Premature patent expirations for BAYER HLTHCARE

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Sign Up ➤ Sign Up

Non-Orange Book US Patents for Bayer Hlthcare

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,713,643 Foamable carriers ➤ Sign Up
8,263,580 Vitamin formulation ➤ Sign Up
8,741,265 Penetrating pharmaceutical foam ➤ Sign Up
9,539,208 Foam prepared from nanoemulsions and uses ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Bayer Hlthcare Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014 00028 Denmark ➤ Sign Up PRODUCT NAME: RIOCIGUAT OG SALTE, ISOMERER OG HYDRATER HERAF; REG. NO/DATE: EU/1/13/907 20140327
0130034 00099 Estonia ➤ Sign Up PRODUCT NAME: REGORAFENIIB;REG NO/DATE: K(2013)5622 (LOPLIK) 26.08.2013
C0022 France ➤ Sign Up PRODUCT NAME: ESTRADIOL ANHYDRE DROSPIRENONE; REGISTRATION NO/DATE IN FRANCE: NL 28661 DU 20040316; REGISTRATION NO/DATE AT EEC: RVG 27505 DU 20021211
2006000059 Germany ➤ Sign Up PRODUCT NAME: SORAFENIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/06/342/001 20060719
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Cerilliant
McKinsey
Covington
Teva
Fish and Richardson
Baxter
Federal Trade Commission
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.